Testosterone & Cardiovascular Health
The Full Picture - Beyond TRAVERSE and the ED-as-Sentinel Link
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
1 human trial, ~5,246 participants (TRAVERSE). The written rationale for this grade is still being prepared.
- FDA
- Not applicable (concept); FDA removed CV black-box language Feb 2025
Reference only. Not medical advice.
What can go wrong
Testosterone therapy can raise hematocrit (erythrocytosis), increasing thrombotic risk, and TRAVERSE flagged more atrial fibrillation, non-fatal arrhythmias, venous thromboembolism, and fractures. Men with recent cardiovascular events, uncontrolled heart failure, or high baseline hematocrit require careful evaluation. Supraphysiological/anabolic dosing carries cardiovascular risks far beyond replacement.
This is something to take to a clinician. The Atlas can tell you what is known about testosterone & cardiovascular health in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The relationship between testosterone and the cardiovascular system has swung from alarm to cautious reassurance. The TRAVERSE trial (~5,246 men) found no increase in major adverse cardiovascular events (MACE) with testosterone vs placebo over a mean ~33 months, prompting the FDA to remove cardiovascular black-box language in February 2025 - though TRAVERSE did flag more atrial fibrillation, non-fatal arrhythmias, venous thromboembolism, and fractures. Layered onto this is the ED-as-sentinel concept: because penile arteries are small, erectile dysfunction often precedes overt coronary disease by years, making ED a practical early warning.
Testosterone's heart story is nuanced - and erectile dysfunction is often the first warning the heart is in trouble.
What it is invoked to explain
Claims this idea is used to support. Whether it supports them is the rest of the entry.
How it works
Testosterone interacts with the cardiovascular system through effects on vascular endothelium, nitric oxide signaling, body composition, insulin sensitivity, and red-cell mass (erythrocytosis raises thrombotic potential). Low testosterone is associated with adverse metabolic profiles, but much of its link to cardiovascular events appears confounded by shared comorbidities rather than being clearly causal. ED and coronary disease share a common substrate - endothelial dysfunction and reduced nitric oxide availability.
The artery-size hypothesis
Erectile dysfunction frequently shows up before a cardiac event because penile arteries are small (roughly 1-2 mm) and clog symptomatically earlier than the larger coronary arteries (roughly 3-4 mm). The same endothelial dysfunction underlies both, so ED can act as a sentinel - often preceding overt coronary disease by a few years. This makes new-onset vasculogenic ED a reason to assess cardiovascular risk, not just to reach for a PDE5 inhibitor.
Safety in detail
Testosterone therapy has cardiovascular implications requiring physician evaluation and monitoring (including hematocrit). New-onset erectile dysfunction should prompt cardiovascular risk assessment rather than self-treatment.
Replacement is not the same as a cycle
TRAVERSE and the reassuring CV data apply to physiological replacement that restores normal testosterone levels in hypogonadal men. They do not extend to supraphysiological or anabolic-steroid dosing, which is associated with cardiomyopathy, adverse lipid changes, polycythemia, and elevated cardiovascular risk.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Hematocrit / hemoglobin
- Blood pressure
- Cardiovascular risk factors and symptoms
- Assessment for arrhythmia symptoms (e.g., AFib)
What people get wrong
Often saidTRAVERSE proves testosterone is good for the heart
ActuallyTRAVERSE was a safety (non-inferiority) trial: it found no increase in MACE, not a cardiovascular benefit, and it flagged increases in AFib, arrhythmia, VTE, and fractures.
Often saidED is just a sexual problem
ActuallyVasculogenic ED is frequently the first sign of systemic vascular disease and can precede a cardiac event by years - it warrants cardiovascular risk evaluation.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
Earlier observational and meta-analytic data on testosterone and cardiovascular risk were mixed and partly confounded; some retrospective and meta-analyses even suggest an inverse association between TRT and events in low-T men, while TRAVERSE provides the strongest randomized medium-term safety evidence to date. The arrhythmia/VTE signals temper an otherwise reassuring picture.
At a glance
- TRAVERSE size
- ~5,246 men
- Follow-up
- mean ~33 months
- Primary MACE
- no significant increase
- Flagged signals
- AFib, arrhythmia, VTE, fractures
- FDA black box removed
- February 2025
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Testosterone & Cardiovascular Health. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
TRAVERSE2023
No significant increase in MACE with testosterone vs placebo in ~5,246 high-CV-risk hypogonadal men; signals for AFib, arrhythmia, VTE, and fractures noted
FDA label change2025
FDA removed cardiovascular black-box warning and required inclusion of TRAVERSE results in testosterone labeling
ED as a sentinel marker of endothelial dysfunction2000s
Established the artery-size hypothesis - small penile vessels are affected before coronary vessels, so ED precedes overt coronary events